Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PD0332991/Paclitaxel in Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01320592
Recruitment Status : Completed
First Posted : March 22, 2011
Last Update Posted : April 8, 2020
Sponsor:
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

Tracking Information
First Submitted Date  ICMJE March 16, 2011
First Posted Date  ICMJE March 22, 2011
Last Update Posted Date April 8, 2020
Actual Study Start Date  ICMJE March 2011
Actual Primary Completion Date May 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 7, 2020)
To Determine the Adverse Events of PD0332991 [ Time Frame: weekly paclitaxel at a fixed dose of 80 mg/m2 and to assess the safety of the combination after 3 cycles of therapy (cycles are 28 days) . ]
To determine the maximally-tolerated dose and safety of PD0332991 in combination with a fixed, weekly dose of Paclitaxel of 80 mg/m2 and to characterize the safety of the combination during the first three cycles of therapy.
Original Primary Outcome Measures  ICMJE
 (submitted: March 21, 2011)
To Determine the Adverse Events of PD0332991
To determine the maximally-tolerated dose and safety of PD0332991 in combination with a fixed, weekly dose of Paclitaxel of 80 mg/m2 and to characterize the safety of the combination during the first three cycles of therapy.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 7, 2020)
  • Maximally Tolerated Dose in an expanded Cohort of Breast Cancer Patients [ Time Frame: weekly paclitaxel at a fixed dose of 80 mg/m2 and to assess the safety of the combination after 3 cycles of therapy (cycles are 28 days) ]
    To explore the activity of the combination at the MTD in an expanded cohort of breast cancer patients.
  • To explore the relationship between selected biomarkers and efficacy, tolerability and safety outcomes [ Time Frame: weekly paclitaxel at a fixed dose of 80 mg/m2 and to assess the safety of the combination after 3 cycles of therapy (cycles are 28 days) ]
    To explore the relationship between selected biomarkers and efficacy, tolerability and safety outcomes
Original Secondary Outcome Measures  ICMJE
 (submitted: March 21, 2011)
  • Maximally Tolerated Dose in an expanded Cohort of Breast Cancer Patients
    To explore the activity of the combination at the MTD in an expanded cohort of breast cancer patients.
  • To explore the relationship between selected biomarkers and efficacy, tolerability and safety outcomes
    To explore the relationship between selected biomarkers and efficacy, tolerability and safety outcomes
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE PD0332991/Paclitaxel in Advanced Breast Cancer
Official Title  ICMJE A Phase 1 Trial of PD0332991 and Paclitaxel in Patients With Rb-Expressing Advanced Breast Cancer
Brief Summary This study is a phase I, single arm, open-label trial of PD0332991 in combination with Paclitaxel in patients with Rb-expressing metastatic breast cancer. Up to 20 patients are anticipated to be enrolled to reach the Maximum Tolerated Dose (MTD) of PD0332991 in combination with Paclitaxel. Once the MTD is established, an additional expanded cohort of 10 patients will be enrolled at that dose to establish the Recommended Phase 2 Dose (RP2D), obtain additional safety data and perform exploratory biomarker studies.
Detailed Description This study is a phase I, single arm, open-label trial of PD0332991 in combination with paclitaxel in patients with Rb-expressing metastatic breast cancer. Patients will be treated as shown in the schema below. Up to 20 patients are anticipated to be enrolled to reach the MTD of PD0332991 in combination with Paclitaxel. Once the MTD is established, an additional expanded cohort of 10 patients will be enrolled at that dose to establish the RP2D, obtain additional safety data and perform exploratory biomarker studies. The primary endpoint will be assessed after one cycle of therapy. Patients will remain on study until dose limiting toxicity, disease progression or physician/patient discretion. Safety assessment will continue for the duration of patient participation.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Cancer
Intervention  ICMJE
  • Drug: PD0332991
  • Drug: Paclitaxel
Study Arms  ICMJE Experimental: PD0332991 and Paclitaxel
PD0332991 in combination with weekly paclitaxel at a fixed dose of 80 mg/m2
Interventions:
  • Drug: PD0332991
  • Drug: Paclitaxel
Publications * Clark AS, McAndrew NP, Troxel A, Feldman M, Lal P, Rosen M, Burrell J, Redlinger C, Gallagher M, Bradbury AR, Domchek SM, Fox KR, O'Dwyer PJ, DeMichele AM. Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer. Clin Cancer Res. 2019 Apr 1;25(7):2072-2079. doi: 10.1158/1078-0432.CCR-18-0790. Epub 2019 Jan 11.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 7, 2020)
28
Original Estimated Enrollment  ICMJE
 (submitted: March 21, 2011)
20
Actual Study Completion Date  ICMJE May 2019
Actual Primary Completion Date May 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patient must have histologically or cytologically-confirmed metastatic breast cancer. Any ER, PR or Her2 status is allowed.
  • Tumor must express Retinoblastoma (Rb) protein, as defined as any measureable staining by immunohistochemistry
  • Male or female and > 18 years of age on the day of signing informed consent.
  • Patient must have received < prior cytotoxic regimens for metastatic breast cancer. This does not include cytoxic regimens used in the adjuvant setting.
  • Performance status of 0-1 on the Eastern Cooperative Oncology Group Performance Scale and life expectancy > 3 months.
  • patient on the dose-escalation portion of the trial must have evaluable disease, defined as either measurable (by RECIST) or non-measurable disease (e.g. bone mets, pleural effusion or lymphangitic spread). Measurable disease is required for patients in the expanded RP2D cohort.
  • The subject must have adequate organ function, defined as follows:

Bilirubin < 1.5 x upper normal limit or calculated creatinine clearance > 60 mL/min, and for subjects without liver metastases: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper normal limit

  • For subjects without extensive bone metastases: alkaline phosphatase levels < 2.5 x upper normal limit .
  • For subjects with extensive bone metastases: alkaline phosphatase levels < 5 x upper normal limit .
  • The subject must have adequate marrow function, defined as follows
  • Absolute neutrophil count (ANC) >1500/mm
  • Platelets > 100,000/mm
  • Hemoglobin > 9 g/dL
  • Female patient of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication and agree to the use of effective methods of contraception while on study.
  • Patient must be capable of, and must voluntarily agree to participate by giving written informed consent.
  • Patient must be able to swallow capsules and has no surgical or anatomical condition that will preclude the patient from swallowing and absorbing oral medications on an ongoing basis.
  • Prior taxane therapy in the adjuvant or metastatic setting is allowed.
  • Concomitant use of biphosphonates is allowed.
  • Patients with stable, treated CNS disease are eligible.

Exclusion Criteria:

  • Patient who has had chemotherapy, radiotherapy or hormonal therapy within 3 weeks (6 weeks for nitrosoureas, mitomycin C or bevacizumab), or who has not recovered from the adverse events due to previous agents administered more than 4 weeks prior to Study Day 1. If the patient has residual toxicity from prior treatment, toxicity must be < Grade 1.
  • patients less than 4 weeks post major surgical procedure (all surgical wounds must be fully healed). For the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia.
  • Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. However, patients with CNS metastases (including brain metastases) who have completed a course of radiotherapy are eligible for the study provided they are clinically stable. Oral corticosteroids for control of CNS symptoms are allowed.
  • Patient has known hypersensitivity to the components of study drug or its analogs.
  • The subject has uncontrolled intercurrent illness including, but not limited to Ongoing or active infection
  • Diabetes mellitus
  • Hypertension
  • Symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months.
  • Patient has baseline neuropathy of > grade 2
  • Patients who have known allergic reactions to Paclitaxel or IV Contrast Dye despite standard prophylaxis.
  • The subject is pregnant or breastfeeding
  • The subject is known to be positive for the human immunodeficiency virus (HIV). Note: baseline HIV screening is not required.
  • The subject is unable eor unwilling to abide by the study protocol or cooperate fully with the investigator or designee.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01320592
Other Study ID Numbers  ICMJE UPCC 02111
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Abramson Cancer Center of the University of Pennsylvania
Study Sponsor  ICMJE Abramson Cancer Center of the University of Pennsylvania
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Abramson Cancer Center of the University of Pennsylvania
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP